Member Info for Runner-Runner

It makes little sense to think they are converting to keep these shares. Why do they need to do that?

It also makes little sense to think that just because they are going to sell them (wouldn't you?) that it means they are concerned.

They still have up to almost 42million shares available to them to convert. They have plenty in the bank to keep over the course of the agreement.

They are simply managing risk and taking good profits while they are there. That is the beauty of how this agreement is set up for them. Of course they are likely to sell them. With the likely connections, they have it makes sense that they have also lined up a buyer for the whole lot as well. So may not even need to sell them through the market.

"So you're equating a level that's 'much higher' than a very small number is better than Standard Doxorubicin treatment levels."

No. I am equating the level of Dox in the bloodstream as much lower from AVA6000 as it would be from standard dox.
Together with finding therapeutic levels of dox in all tumours, thus proving the concept that AVA6000 is working as intended and is indeed better than Standard Dox.

"You can see that these two statements are completely seperate measurements and can't be directly compared don't you?"

Yes. Which is why I wasn't comparing those 2 measurements. Only you can explain why you were. Maybe it's got something to do with the Affimers you also think are present in AVA6000?

"No one on this board knows how good AVA6000 is compared to standard Doxorubicin."

We don't have the formula to determine that no. We have been told however that it is working better than standard dox. As Retireby40 posted below.

This analysis shows that AVA6000 targets the release of doxorubicin to the tumour tissue at therapeutic levels which are much higher than the levels being detected in the bloodstream at the same timepoint.

Much higher therapeutic levels in the tumour than in the bloodstream. Better then than standard dox as standard dox is NOT selective and therefore more equally distributed.

What part of the above are you disputing?

Touk,

Good question.

I presume Alastair has an open-door policy for Big Pharma and that anything and everything is potentially up for sale at the right price. Whether or not Big Pharma has access to more detailed data than us is debatable. What is certain though is that they will understand the meaning and potential of the data much better than we PI's.

They are either not interested or they are in discussions. If I could buy shares in Avacta's contract lawyers right now, I would!

Until Al's letter in the times the other day I was taking the science day at face value. His letter and its timing seem to suggest that it's the last chance saloon for the UK investment community to take positions. We have done plenty of "investment seminars" before and seemingly had very little action/buying on the back of it. An attempt to raise the price whilst in discussions with Big Pharma. An attempt to stave off lowball bids? Who knows? We are all guessing to a degree.

Dig,

Absolutely no idea obviously. I think the recent diagnostics deal they did at least showed they have prepared themselves for a possible buyout of the entire therapeutics platform. Giving themselves a solid business to continue with.

Ultimately I believe our future is in the hands of Big Pharma one way or another.

Whilst I would love to see Avacta cling on the tech as long as possible and go down the licencing/royalty route. That may not be possible.

Quite BV.

The Affimer, pre|CISION, TMAC tree is an enormous one. It has many current known branches of potential commercialisation and no doubt many more unknown branches yet to come.

To think that Acacta could and should try to develop and monetise this tech all on its own, with all of the associated risks is folly.

It doesn't even need to, is the point. Avacta has it all right now and can choose to keep as many in-house programs as they can comfortably and profitably deal with.

They can sell/license the tech out in any number of different ways, through any number of different deals.

Every deal they do can only help accelerate the tech to market, assist in accelerating Avacta's chosen in-house programs and help Avacta to grow ever more branches on the tree.

Allowing big pharma in can only be of help in getting the most out of this multi-faceted technology.

The big question is - Does Big Pharma want in at all? Do they see enough of an investment case here to open up the cheque book for any part of this tree? Big Pharma doesn't get to be Big Pharma by turning their backs on brilliant investment cases. This is the validation I am keen to see now. Avacta has validated the platforms IMHO. Big Pharma needs to give it its stamp of approval in currencies other than just LinkedIn Likes!

One sniff of a deal to ignite an epic re-rate?

It isn't just about AVA6000 Wyn.

Big Pharma needs to get involved to speed up delivery of the entire platform of drugs that the pre|CISION tech can produce and the inevitable "new" discoveries that pre|CISION could unlock in the future.

Avacta on it's own can likely just do 1 thing at a time. Big Pharma can do many trials/studies concurrently.

Part 2

We can all shout as loud as we like about what we have. Until big pharma start writing cheques the investment case is not truly proven. Any deal that gives Big Pharma access to our pre|CISION platform at any level is needed to truly prove the investment case here. Right now, we have no deals, we have no rumours of deals. We have investors thinking they have outsmarted the richest Big Pharmas on the planet. One cheque is all that is needed to prove it.
What is holding back Big Pharma from wanting in now. Pre 1b. Pre DE5?
They need more Data some will cry.

Do they?

We don’t. We are convinced.
The trial is “designed to be data rich”. The data delivered so far is good enough for us.
Think about the “delay” in starting 1b due to continuing to escalate to find MTD. There must be a very good argument to suggest that this “data rich” study will throw up enough good data as we progress to MTD, to answer a lot of the questions 1b seeks to answer and give a measurable improvement to the eventual timeline of the 1b study?

We must surely be close to the first Big Pharma making some kind of move. The first mover advantage yields such a potentially massive prize, financially and humanitarian.

Back in the tumbleweed days of Avacta when a dozen total trades a week would be considered "frenzied" activity and you could count the number of BB posts in a month on the fingers of 1 hand, I truly began to think I was crazy.

Pre Covid, pre-Myles M, pre-LG Chem, etc my research into the potential of Affimers, pre|CISION & TMAC was throwing up MCAP valuations of anywhere between $2b - $20b. For a company with around 100m shares in issue at the time at around 20p per share, I was looking at possible future SP's in the region of £20 - £200 per share. All for a tiny Biotech in Wetherby that almost no one had ever heard of!

I had begun selling up most of my "trustworthy" funds in my SIPP and ISA and sinking the proceeds into the sheer lunacy of my research. Apart from the odd crazy on the "other" bulletin board (Hustbot under his Viking moniker being one), no one else shared my enthusiasm or vision for Avacta's future. Avacta's terrible commercial history up to that point would scare away the grim reaper!

Out of the blue came Myles McNulty, his shining armour illuminating the darkness in my mind. Finally, I was no longer the only lunatic in the asylum. Then, as now, he brought very little "new" information to the table that my own research had missed. Then, as now, he had the ability to put his expert case into words much better than I could ever do, making sense of the jumbled madness in my head.

Fast forward to today and the company and its battle-hardened investors stand on the precipice of greatness.

We all agree that the platform has now been proven. Dox is present in 100% of biopsies and present at therapeutic levels. It works - it's unequivocal. From what we know of Dox and what we know is now proven of AVA6000 we, as investors, conclude that it is ALREADY a better product than straight dox and that only time and investment are now needed to make all these years of Avacta's work and all these years of teeth-gritting patience from investors pay off.

We all think we have a $multi-billion technology platform in our hands. However, this journey is not yet done. I spoke a couple of weeks ago about the need for us as investors and of mankind, as cancer sufferers, for Big Pharma to really "need" what we have. If Avacta goes it alone, the time and investment required to bring the whole platform of "targeted chemo with no side effects" to market are huge. The payback for mankind and investors will be a long time coming. Morally speaking far too long for Mankind.

Ahh. But are you also a rugby legend BITL?

Very.

And he turned at just exactly the start of the gap close bounce too!

Jeez,

It doesn't take much for all you long and strong holders to throw your toys out of the pram.

Take advantage of this gap closure process and do the DITRA chomp!

Interesting how few of you here believe in the power of the gap and yet totally believe on a regular basis that Market Makers are "manipulating" the price action.

In stocks that attract a lot of traders the MM's know that there will be an awful lot of volume at or near these gaps. Since they make their money on trading volume it makes perfect sense that MM's will look to close the gap quickly as it gets within grabbing distance.

I too bought at 143.96 this morning eyeing the gap close and knowing that if it actually gets there it will likely go NT to buy in any case so happy to get in a penny or 2 higher at what I believe to be a great price.

Surely if you believe in MM manipulation you should also believe that they will hunt down the gaps?

"It’s called a opinion"

It isn't though. It's called an agenda made to look like an opinion. Much like all your posts so far.

You are making an awful lot of fuss about nothing Touk.

If and when they require the services of an LFT manufacturer I would hope that they would do a bit more due diligence than, " oh look, one of our ex-employees works there, let's do a deal".

The romanticism around this company from people here is silly.

This is business. Hard-nosed, cold-hearted, money-making business. Somewhere along the line, some people here seem to have forgotten that.

Indeed.

And so Avacta fires the starting pistol of one of the most fascinating games of Big Pharma Chicken ever seen.

Which one is going to blink first?

They have already given us the cash.

Part of the way we pay back is by issuing more shares.

Alan is actually Santa and he hurt his back carrying the massive sack for the Takeda boss.

Obvs

Lol

This already seems to be shaping for a day of, "Let's all think of excuses for Alan".

It is a romantic notion that Avacta can stay independent long enough and retain full ownership of most of its platforms long enough to become a pharma giant, thus extracting maximum long-term shareholder value for us all.

However, the longer we stay independent the more likely it is that we don't actually have what big pharma really wants, making it more unlikely we achieve greatness on our own (notwithstanding the huge amounts of cash we would need to do it on our own in the first place).

This is business. We really need to have what big pharma wants to make good returns here. The quicker the better in my view.

Buying LD was (IMHO) a genius move on many fronts.

Big cash runway.
Positively cash generative to service the debt and decrease overall cash burn.
A message to the market that "we could do this on our own if you don't come up with some serious offers".
A profitable business to continue with and grow from should therapeutics be sold.